

Response to comments on: "The Influence of Wall Stress on AAA Growth and Biomarkers"

Dear Editor,

I thank Dr. Georgakarakos and colleagues for their letter in response to our article. We attempted to predict AAA growth based on relative wall stress. We found a lower growth rate for the group of AAAs with a relative low wall stress.¹ However, AAA growth is most likely a multi-factorial phenomenon, possibly including the effects of flow through the AAA. It is known that AAAs grow faster when they increase in size. Also the amount of thrombus grows, narrowing the flow lumen to a comparable size as the healthy aorta, only the flow lumen is more tortuous in AAAs. Additionally, the endothelial cells normally covering the vessel wall are destroyed and can therefore not respond to shear stresses induced by secondary flows. Our group previously developed FSI models of AAAs² and, among others, we will further investigate the relation between aneurysmal flow, thrombus and AAA growth. Additionally we will evaluate these models to study the relation between wall stress, flow effects, circulating biomarkers and AAA growth in a larger patient population.

References

- 1 Speelman L, Hellenthal FA, Pulinx B, Bosboom EM, Breeuwer M, van Sambeek MR, et al. The influence of wall stress on AAA growth and biomarkers. *Eur J Vasc Endovasc Surg* 2010;**39**:410–6.
- 2 Wolters BJ, Rutten MC, Schurink GW, Kose U, de Hart J, van de Vosse FN, et al. A patient-specific computational model of fluid-structure interaction in abdominal aortic aneurysms. *Med Eng Phys* 2005;**27**(10):871–83.

L. Speelman*

*Department of Biomedical Engineering,
Erasmus Medical Center Rotterdam,
PO Box 2040, 3000 CA Rotterdam, The Netherlands*

*Corresponding author. Tel.: +31 10 7044039;
fax: +31 10 7044720.

E-mail address: l.speelman@erasmusmc.nl

F.A. Hellenthal

*Department of General Surgery, Maastricht
University Medical Center, The Netherlands*

B. Pulinx

*Department of Clinical Chemistry, Maastricht
University Medical Center, The Netherlands*

E.M. Bosboom

*Department of Biomedical Engineering, Maastricht
University Medical Center, The Netherlands
Department of Biomedical Engineering,
Eindhoven University of Technology, The Netherlands*

M. Breeuwer

*Philips Healthcare, Department of
Clinical and Healthcare Informatics, The Netherlands*

M.R. van Sambeek

*Catharina Hospital Eindhoven, Department of Vascular
Surgery, The Netherlands*

F.N. van de Vosse

*Department of Biomedical Engineering, Maastricht
University Medical Center, The Netherlands
Department of Biomedical Engineering, Eindhoven
University of Technology, The Netherlands*

M.J. Jacobs

*Department of General Surgery, Maastricht
University Medical Center, The Netherlands*

W.K. Wodzig

*Department of Clinical Chemistry, Maastricht University
Medical Center, The Netherlands*

G.W. Schurink

*Department of General Surgery, Maastricht University
Medical Center, The Netherlands*

Available online 18 April 2010

© 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

doi:10.1016/j.ejvs.2010.03.026

Comment on "Variations in the Pharmacological Management of Patients Treated with Carotid Endarterectomy: A Survey of European Vascular Surgeons"

Dear Editor,

We noted with interest the persistent variation in perioperative Clopidogrel management at the time of carotid endarterectomy (CEA) as documented by Hamish et al (*Eur J Vasc Endovasc Surg* 2009;**38**:402–7). The authors demonstrate that 43% and 55% of surgeons queried would stop Clopidogrel prior to CEA for both symptomatic and asymptomatic patients respectively.

Furthermore, the authors noted that over 49% of surgeons would stop Clopidogrel more than 7 days prior to surgery, irrespective of a patient's symptomatic status. Presumably, these clinical biases reflect a presumption that Clopidogrel is associated with increased serious bleeding complications at the time of CEA. Further, in symptomatic patients, it suggests that surgeons who stop Clopidogrel are more concerned about operative bleeding than about antiplatelet efficacy perioperatively.

In a recent study conducted by the Vascular Study Group of New England, we evaluated 4587 CEAs performed by 66 surgeons in the United States. Though our analysis focused